S&P 500   3,244.71 (-2.14%)
DOW   26,786.90 (-1.84%)
QQQ   264.11 (-3.07%)
AAPL   107.34 (-4.00%)
MSFT   201.10 (-3.05%)
FB   248.94 (-2.28%)
GOOGL   1,408.93 (-3.49%)
AMZN   3,007.23 (-3.89%)
NVDA   486.64 (-3.73%)
TSLA   376.64 (-11.22%)
BABA   272.36 (-1.06%)
CGC   14.45 (-9.91%)
GE   6.13 (-1.92%)
MU   49.82 (+0.24%)
AMD   74.75 (-3.80%)
T   27.98 (-1.86%)
F   6.66 (-1.77%)
ACB   5.17 (-29.37%)
GILD   63.36 (-0.06%)
NFLX   471.43 (-4.02%)
DIS   123.13 (-3.21%)
BAC   23.45 (-2.05%)
BA   151.11 (-3.63%)
S&P 500   3,244.71 (-2.14%)
DOW   26,786.90 (-1.84%)
QQQ   264.11 (-3.07%)
AAPL   107.34 (-4.00%)
MSFT   201.10 (-3.05%)
FB   248.94 (-2.28%)
GOOGL   1,408.93 (-3.49%)
AMZN   3,007.23 (-3.89%)
NVDA   486.64 (-3.73%)
TSLA   376.64 (-11.22%)
BABA   272.36 (-1.06%)
CGC   14.45 (-9.91%)
GE   6.13 (-1.92%)
MU   49.82 (+0.24%)
AMD   74.75 (-3.80%)
T   27.98 (-1.86%)
F   6.66 (-1.77%)
ACB   5.17 (-29.37%)
GILD   63.36 (-0.06%)
NFLX   471.43 (-4.02%)
DIS   123.13 (-3.21%)
BAC   23.45 (-2.05%)
BA   151.11 (-3.63%)
S&P 500   3,244.71 (-2.14%)
DOW   26,786.90 (-1.84%)
QQQ   264.11 (-3.07%)
AAPL   107.34 (-4.00%)
MSFT   201.10 (-3.05%)
FB   248.94 (-2.28%)
GOOGL   1,408.93 (-3.49%)
AMZN   3,007.23 (-3.89%)
NVDA   486.64 (-3.73%)
TSLA   376.64 (-11.22%)
BABA   272.36 (-1.06%)
CGC   14.45 (-9.91%)
GE   6.13 (-1.92%)
MU   49.82 (+0.24%)
AMD   74.75 (-3.80%)
T   27.98 (-1.86%)
F   6.66 (-1.77%)
ACB   5.17 (-29.37%)
GILD   63.36 (-0.06%)
NFLX   471.43 (-4.02%)
DIS   123.13 (-3.21%)
BAC   23.45 (-2.05%)
BA   151.11 (-3.63%)
S&P 500   3,244.71 (-2.14%)
DOW   26,786.90 (-1.84%)
QQQ   264.11 (-3.07%)
AAPL   107.34 (-4.00%)
MSFT   201.10 (-3.05%)
FB   248.94 (-2.28%)
GOOGL   1,408.93 (-3.49%)
AMZN   3,007.23 (-3.89%)
NVDA   486.64 (-3.73%)
TSLA   376.64 (-11.22%)
BABA   272.36 (-1.06%)
CGC   14.45 (-9.91%)
GE   6.13 (-1.92%)
MU   49.82 (+0.24%)
AMD   74.75 (-3.80%)
T   27.98 (-1.86%)
F   6.66 (-1.77%)
ACB   5.17 (-29.37%)
GILD   63.36 (-0.06%)
NFLX   471.43 (-4.02%)
DIS   123.13 (-3.21%)
BAC   23.45 (-2.05%)
BA   151.11 (-3.63%)
Log in
NASDAQ:CARA

Cara Therapeutics Stock Forecast, Price & News

$13.82
-0.34 (-2.40 %)
(As of 09/23/2020 03:15 PM ET)
Add
Compare
Today's Range
$13.72
Now: $13.82
$14.18
50-Day Range
$14.15
MA: $15.82
$17.43
52-Week Range
$8.88
Now: $13.82
$26.67
Volume20,198 shs
Average Volume493,078 shs
Market Capitalization$647.98 million
P/E RatioN/A
Dividend YieldN/A
Beta1.7
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with chronic kidney disease (CKD) associated pruritus undergoing hemodialysis, as well as in Phase II/III clinical trial for the treatment of dialysis patients suffering from chronic kidney disease-associated pruritus. The company is also developing Oral KORSUVA (CR845/difelikefalin) that is in Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; and in Phase I clinical trial for treating pruritus chronic liver disease. In addition, it is developing CR845/difelikefalin Injection, which is in Phase III clinical trial for the treatment of acute post-operative pain; and Oral CR845/difelikefalin that has completed Phase IIb for treating chronic pain, as well as CR701, which is in preclinical trial for the treatment of chronic pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.
Read More
Cara Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.54 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CARA
CUSIPN/A
Phone203-406-3700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$19.89 million
Book Value$4.66 per share

Profitability

Net Income$-106,370,000.00
Net Margins-480.55%

Miscellaneous

Employees55
Market Cap$647.98 million
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$13.82
-0.34 (-2.40 %)
(As of 09/23/2020 03:15 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CARA News and Ratings via Email

Sign-up to receive the latest news and ratings for CARA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cara Therapeutics (NASDAQ:CARA) Frequently Asked Questions

How has Cara Therapeutics' stock been impacted by COVID-19?

Cara Therapeutics' stock was trading at $13.43 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CARA shares have increased by 2.9% and is now trading at $13.82.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Cara Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Cara Therapeutics
.

When is Cara Therapeutics' next earnings date?

Cara Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Cara Therapeutics
.

How were Cara Therapeutics' earnings last quarter?

Cara Therapeutics Inc (NASDAQ:CARA) posted its earnings results on Monday, August, 10th. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.68) by $0.14. The biopharmaceutical company earned $5.63 million during the quarter, compared to analysts' expectations of $5.48 million. Cara Therapeutics had a negative return on equity of 65.97% and a negative net margin of 480.55%.
View Cara Therapeutics' earnings history
.

What price target have analysts set for CARA?

4 analysts have issued 1 year price targets for Cara Therapeutics' stock. Their forecasts range from $30.00 to $40.00. On average, they anticipate Cara Therapeutics' share price to reach $34.50 in the next year. This suggests a possible upside of 149.6% from the stock's current price.
View analysts' price targets for Cara Therapeutics
.

Who are some of Cara Therapeutics' key competitors?

What other stocks do shareholders of Cara Therapeutics own?

Who are Cara Therapeutics' key executives?

Cara Therapeutics' management team includes the following people:
  • Dr. Derek T. Chalmers, Co-Founder, Pres, CEO & Director (Age 55)
  • Dr. Frédérique Menzaghi, Chief Scientific Officer and Sr. VP of R&D (Age 53)
  • Dr. Joana Goncalves, Chief Medical Officer (Age 45)
  • Dr. Joseph Stauffer, Consultant (Age 53)
  • Dr. Michael E. Lewis, Co-Founder & Chief Scientific Advisor (Age 67)

What is Cara Therapeutics' stock symbol?

Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."

Who are Cara Therapeutics' major shareholders?

Cara Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include RHO Capital Partners Inc. (5.98%), Vanguard Group Inc. (4.81%), Bank of America Corp DE (2.14%), Nuveen Asset Management LLC (1.07%), Pinnacle Associates Ltd. (0.88%) and Goldman Sachs Group Inc. (0.69%). Company insiders that own Cara Therapeutics stock include Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joana Goncalves, Joseph William Stauffer, Mani Mohindru and Scott Terrillion.
View institutional ownership trends for Cara Therapeutics
.

Which major investors are selling Cara Therapeutics stock?

CARA stock was sold by a variety of institutional investors in the last quarter, including RHO Capital Partners Inc., Vanguard Group Inc., UBS Group AG, California Public Employees Retirement System, B. Riley Wealth Management Inc., Pinnacle Associates Ltd., Advisor Group Holdings Inc., and Commonwealth Equity Services LLC. Company insiders that have sold Cara Therapeutics company stock in the last year include Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joana Goncalves, Mani Mohindru, and Scott Terrillion.
View insider buying and selling activity for Cara Therapeutics
.

Which major investors are buying Cara Therapeutics stock?

CARA stock was purchased by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Goldman Sachs Group Inc., Bank of America Corp DE, SG Americas Securities LLC, Prosight Management LP, Aigen Investment Management LP, Two Sigma Advisers LP, and Marshall Wace North America L.P..
View insider buying and selling activity for Cara Therapeutics
.

How do I buy shares of Cara Therapeutics?

Shares of CARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cara Therapeutics' stock price today?

One share of CARA stock can currently be purchased for approximately $13.82.

How big of a company is Cara Therapeutics?

Cara Therapeutics has a market capitalization of $647.98 million and generates $19.89 million in revenue each year. The biopharmaceutical company earns $-106,370,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. Cara Therapeutics employs 55 workers across the globe.

What is Cara Therapeutics' official website?

The official website for Cara Therapeutics is www.caratherapeutics.com.

How can I contact Cara Therapeutics?

Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The biopharmaceutical company can be reached via phone at 203-406-3700 or via email at [email protected]

This page was last updated on 9/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.